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Treatment of rat glomerular mesangial cell (GMC) cultures
with pancreatic secreted phospholipase A2 (sPLA2-IB) results
in an enhanced expression of sPLA2-IIA and COX-2, possibly
via binding to its specific M-type sPLA2 receptor. In the
current study, we have investigated the expression and
regulation of sPLA2-IB and its receptor during
glomerulonephritis (GN). In vivo we used the well-established
rat model of anti-Thy 1.1 GN (anti-Thy 1.1-GN) to study the
expression of sPLA2-IB and the M-type sPLA2 receptor by
immunohistochemistry. In addition, in vitro we determined
the interkeukin (IL)-1b-regulated mRNA and protein
expression in primary rat glomerular mesangial and
endothelial cells as well as in rat peripheral blood leukocytes
(PBLs). Shortly after induction of anti-Thy 1.1-GN, sPLA2-IB
expression was markedly upregulated in the kidney at 6–24 h.
Within glomeruli, the strongest sPLA2-IB protein expression
was detected on infiltrated granulocytes and monocytes.
However, at the same time, the M-type receptor was also
markedly upregulated on resident glomerular cells. In vitro,
the most prominent cytokine-stimulated secretion of
sPLA2-IB was observed in monocytes isolated from rat PBLs.
Treating glomerular endothelial cells (GECs) with cytokines
elicited only weak sPLA2-IB expression, but treatment of
these cells with exogenous sPLA2-IB resulted in a marked
expression of the endogenous sPLA2-IB. Mesangial cells did
not express sPLA2-IB at all. The M-type sPLA2 receptor
protein was markedly upregulated on cytokine-stimulated
mesangial and endothelial cells as well as on lymphocytes
and granulocytes. During anti-Thy 1.1 rat GN, sPLA2-IB and
the M-type sPLA2 receptor are induced as primary
downstream genes stimulated by inflammatory cytokines.
Subsequently, both sPLA2-IB and the M-type sPLA2 receptor
are involved in the autocrine and paracrine amplification of
the inflammatory process in different resident and infiltrating
cells.
Kidney International (2006) 70, 1251–1260. doi:10.1038/sj.ki.5001664;
published online 9 August 2006
KEYWORDS: sPLA2; glomerulonephritis; inflammation; sPLA2 M-type recep-
tor; glomerular cell; immune cell
During the past 4 years, evidence was accumulated concern-
ing the important roles of low-molecular-weight secreted
phospholipases A2 in inflammatory diseases (for a review, see
Granata et al.1 and Kudo and Murakami2). Among the
different sPLA2s, the pancreatic secreted phospholipase A2
(sPLA2-IB) was described to be markedly elevated in the
kidney during both experimental and human acute pancrea-
titis.3,4 Moreover, in the circulation of patients suffering from
chronic renal failure, sPLA2-IB levels were found to be
10-fold higher than in controls.5
Circulating sPLA2-IB seems to be involved in eicosanoid
biosynthesis, as the intravenous infusion of sPLA2-IB in
guinea pigs resulted in increased plasma concentrations of
prostacyclin, prostaglandin E2, and thromboxane B2.
4 These
modifications are accompanied by changes in organ function
such as decrease in blood pressure, heart rate, and base
excess. The role, however, of sPLA2-IB in the initiation of the
arachidonic acid cascade is still unclear, because the enzyme
by itself has virtually only little capacity to directly release
arachidonic acid.6 In vitro studies have shown that treatment
of GMCs with sPLA2-IB stimulated cell proliferation and
eicosanoid formation by activating the mitogen-activated
protein kinase cascade and cytosolic phospholipase A2.
7 The
activation of eicosanoid biosynthesis in these cells did not
require the intrinsic enzymatic activity of sPLA2-IB as a
catalytically inactive mutant could also trigger eicosanoid
production.8 Our recent studies have also shown that sPLA2-
IB can potentiate the cytokine-stimulated transcription of the
proinflammatory sPLA2-IIA via activation of peroxisome
proliferator-activated receptor a in rat mesangial cells.9 This
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effect is also independent of the sPLA2-IB catalytic activity,
but may be mediated by binding of sPLA2-IB to the rat
M-type sPLA2 receptor.
8–14
Based on these in vitro studies, we sought to find out
whether sPLA2-IB and its M-type sPLA2 receptor are
upregulated during mesangioproliferative glomerulonephritis
(GN). The rat model of anti-Thy 1.1 GN (anti-Thy 1.1-GN)
has been used for these studies. This model is based on the
rat-specific expression of the glycoprotein Thy-1 on GMCs.
The recognition of this protein by the specific anti-Thy-1
antibody OX-7 results in a selective complement-dependent
lysis of the mesangium, which is subsequently renewed
during a mesangial-proliferative response.15 The acute injury
typically occurs between 1 h and 2 days after induction of the
disease and is followed by a rapid proliferation of the
endothelial and mesangial cells within the injured glomeruli.
Neutrophils and ED-1-positive macrophages are also present
during the acute lytic phase.16,17 The mesangial cell lesion
induced by the anti-Thy1.1 antibody is a useful model system
to study GMC responses to injury like the expression of
a-smooth muscle-specific actin,18 or the accumulation of
extracellular matrix within the mesangium.19 A major role in
the pathogenesis of this experimental disease plays the
activation of complement including the assembly of the
C5b-9 membrane attack complex.20 This complex promotes
a rapid induction of proinflammatory mediators such as
monocyte chemoattractant protein-121 macrophage inflam-
matory protein-2,22 and, moreover, via cytosolic to nuclear
translocation of the transcription factor nuclear factor kappa
B,23 the formation of nitric oxide. As this is the most
important,24 but not sufficient,25 signal for the induction of
the inducible form of nitric oxide synthase, the formation of
the C5b-9 membrane attack complex triggers the production
of nitric oxide, which is a crucial mediator in the induction of
other genes, thus promoting the severity of the disease.26–30
Despite its role as a potent inductor of nitric oxide, the C5b-9
complex has no influence on sPLA2 expression or activity in
GECs.31
The expression and localization of cyclooxygenase (COX)
isoforms and cytosolic phospholipase A2 have been docu-
mented in this model of GN in a previous study.32 This study
has also shown that prostaglandins generated through the
activation of cPLA2 and COX-1 and COX-2 are potent
mediators of mesangial cell injury. Here, we have observed
that the expression of sPLA2-IB and its receptor are markedly
increased at the mRNA and protein levels during the
development of the anti-Thy 1.1-GN, reaching a maximum
increase at 6–24 h after induction of the disease and
decreasing at later time points. Expression analysis on
isolated cells reveals that sPLA2-IB is strongly produced by
cytokine-activated monocytes and sPLA2-IB-activated en-
dothelial cells in a positive feedback loop, but not by
activated mesangial cells. On the other hand, the M-type
receptor is upregulated by cytokines in resident mesangial
and endothelial cells as well as in infiltrating lymphocytes and
granulocytes.
RESULTS
Expression of sPLA2-IB in rat kidney with anti-Thy 1.1 GN
We first investigated the expression levels of sPLA2-IB in total
extracts of rat kidneys at different time points after Thy-1
induction compared to control kidneys. Semiquantitative
(Figure 1a) and real-time reverse transcription-polymerase
chain reaction (RT-PCR) (Figure 1b) indicate very low levels
of mRNA expression in control kidneys. After induction of
Thy 1.1 GN, the mRNA expression of sPLA2-IB increases,
reaching a maximum at 6 h, and then decreases at later time
points to return to control levels after 7–14 days. The Western
blot analyses were in accordance with a delayed increase in
sPLA2-IB protein in total kidney extracts after 6 h, reaching
maximal steady-state levels at 24 h (Figure 1c). The two
discrete bands observed at about 14 and 15 kDa probably
correspond to mature sPLA2-IB and its proenzyme.
33 As an
control for equal loading of protein, we included Western
blot analyses of b-actin (Figure 1d).
In order to study the location of sPLA2-IB protein in rat
kidney, we first performed immunohistochemical analysis
with a specific rat sPLA2-IB antibody, which does not
crossreact with recombinant or native sPLA2-IIA, sPLA2-V, or
sPLA2-X (Kortesuo et al.
34 and own observations). A weak
staining was observed in the glomeruli of control kidney
(Figure 2a), and no staining was found in the surrounding
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Figure 1 | Expression of sPLA2-IB in kidneys of rats with anti-Thy
1.1-GN. Anti-Thy-1.1 GN was induced in rats by injection of a
monoclonal anti-Thy-1.1 antibody (OX-7) as described in Materials
and Methods. Animals were killed at the indicated time points, and
RNA was extracted from kidneys to perform (a) semiquantitative or
(b) quantitative RT-PCR for detection of sPLA2-IB mRNA expression.
GAPDH was used for standardization. The experiments were
performed three times with comparable results. The values in
(b) represent the means7s.d. of three independent series. *Po0.05.
(c) Western blot analysis for the detection of sPLA2-IB in protein
homogenates of rat kidneys was performed with a specific rat
anti-sPLA2-IB antibody as described in Materials and Methods in
four independent series with comparable results. (d) Detection of
b-actin as a loading control.
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structures of the cortex. In contrast, 6 (Figure 2b) and 24 h
(Figure 2c) after the induction of the disease, a strong
staining was detectable in the glomeruli. In the vicinity as
well as in the interstitium, a weak staining was visible. The
negative control without primary antibody gave no staining
(Figure 2d).
Detection of sPLA2-IB in invading immune cells in the kidney
The time course of sPLA2-IB upregulation and immuno-
staining in the kidney sections suggested that early invading
immune cells like monocytes and granulocytes17 may be the
primary source for the production of sPLA2-IB. Parallel
immunostaining of kidney sections with a specific monoclonal
anti-rat HIS-48 antibody (Figure 3c), a surface marker for rat
neutrophils,22 and with the sPLA2-IB antibody (Figure 3b)
shows that 6 h after disease induction the neutrophils express
sPLA2-IB in the glomeruli. Figure 3d shows merging of both
stainings. Sections of the control kidneys are negative for HIS-
48 as well as for sPLA2-IB (Figure 3a). At 24 h, the staining
with HIS-48 antibody was reduced, indicating that the number
of neutrophils decreased at later time points (not shown).
Before incubation of the sections, it was necessary to block all
immunoglobulin (Ig)G of mouse origin present from the OX-
7 antibody, which has been used to induce the disease.
Monocytes also invade the glomeruli during the first
24 h.17 Using the specific monocyte marker ED-1, we
observed a strong increase in ED-1-positive cells after 6 h
(Figure 3g) in parallel to the increase in sPLA2-IB expressing
cells (Figure 3f). However, approximately half of the ED-1-
positive cells are reactive for sPLA2-IB (Figure 3h). Sections
of the control kidneys showed not more than 1-2 ED-1-
positive cells (Figure 3e). The negative controls, which have
been pretreated with an anti-IgG antibody, gave no signal
without the primary antibodies (not shown).
Expression of sPLA2-IB in rat glomerular mesangial and
endothelial cells in culture
To further identify the type of glomerular cells that express
sPLA2-IB and to study the regulation of sPLA2-IB expression
under typical inflammatory conditions, we isolated different
glomerular and blood cell types and treated them with IL-1b
or tumor necrosis factor alpha (TNFa) alone, or with
exogenously added sPLA2-IB from bovine pancreas and
H48Q-sPLA2-IB, a catalytically inactive recombinant mutant
of the enzyme. First, we studied the expression of sPLA2-IB at
the mRNA and protein levels in rat glomerular mesangial and
endothelial cells under resting, cytokine-treated, or sPLA2-IB
(wild-type and mutant enzyme)-treated conditions. Unsti-
mulated GECs express low levels of sPLA2-IB mRNA, whereas
mesangial cells express no sPLA2-IB at all (Figure 4a). In
agreement with this result, we could detect by Western blot
analysis the mature sPLA2-IB protein and its proenzyme in
cell culture supernatants of GECs (Figure 4b), but not in
those from mesangial cells. The stimulation of GECs with
IL-1b and TNFa did not markedly enhance the expression of
sPLA2-IB at the mRNA or protein levels. However, exogen-
ously added WT-sPLA2-IB as well as H48Q-sPLA2-IB
strongly induces the expression of the endogenous sPLA2-
IB-mRNA (Figure 4a). Western blot analysis was not possible
because of a crossreaction of the rat anti-sPLA2-IB antibody
with the exogenously added sPLA2-IB from bovine pancreas
(Sigma, Taufkirchen, Germany) as well as with the recombi-
nant mutant H48Q- sPLA2-IB.
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Figure 2 | Immunohistochemical analysis of sPLA2-IB expression
in rat kidneys after induction of anti-Thy 1.1-GN. After induction
of anti-Thy 1.1-GN, as described in Materials and Methods, rats
were killed after 6 or 24 h, and kidneys were fixed in formalin and
embedded in paraffin. The same was carried out with kidneys from
healthy control rats. Immunohistochemistry was performed in 5 mm
sections with the primary antibody against sPLA2-IB (1:500) and with
alkaline phosphatase-conjugated goat anti-rabbit IgG (1:100) as
secondary antibody as described in Materials and Methods. Pictures
were taken from the stained sections at a 1:400 magnification.
(a) Control kidney; (b) 6 h after disease induction; (c) 24 h after
disease induction; and (d) negative control without primary
antibody 6 h after disease induction.
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Figure 3 | Colocalization of sPLA2-IB and HIS-48 or ED-1. (a–d)
Colocalization of sPLA2-IB and HIS-48 or (e–h) ED-1 by confocal laser
scanning microscopy original (magnification  400) was performed
in paraffin sections of kidneys taken at 6 h after disease induction.
The sections have been pretreated with an anti-mouse IgG antibody
(c¼ 0.5mg/ml). The sPLA2-IB antibody was used at a 1:400 dilution and
the secondary Alexa 488-conjugated goat anti-rabbit IgG (green) at a
1:400 dilution. For detection of HIS-48, a mouse monoclonal anti-HIS-
48 antibody was used at a 1:2 dilution. ED-1 detection was performed
with a mouse monoclonal anti-ED-1 antibody (1:2 dilution). In both
cases, we used as the secondary antibody Alexa 594-conjugated goat
anti-mouse IgG (red) at a 1:400 dilution. Merge – colocalization of
sPLA2-IB and HIS-48 or ED-1 antibodies.
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We next analyzed the expression of sPLA2-IB in mono-
cytes, lymphocytes, and granulocytes isolated from rat
peripheral blood leukocytes (PBLs) under resting conditions
or after stimulation with IL-1b for different times. Rat
monocytes constitutively express sPLA2-IB mRNA (Figure
5a) and protein (Figure 5b). Interestingly, after IL-1b
treatment, mRNA expression decreased, whereas protein
secretion into the cell culture supernatant increased. This
might indicate that the cells constitutively synthesize, and,
under inflammatory conditions, release sPLA2-IB while the
mRNA is degraded after cytokine treatment.
Another important source for sPLA2-IB are granulocytes.
The expression of sPLA2-IB mRNA is very strong 6 h after the
cytokine treatment (Figure 5a). High amounts of sPLA2-IB
are found in the lysates of these cells with a maximum at 6 h
after IL-1b stimulation (Figure 5b). b-Actin expression was
shown as a loading control (Figure 5c).
In contrast, in unstimulated lymphocytes sPLA2-IB
mRNA is not detectable, but it is upregulated at 2 h after
IL-1b treatment (Figure 5a). However, there is nearly no
production of protein (Figure 5b) and no protein release is
detectable by lymphocytes (not shown).
Together, these results suggest that during the early phases
of mesangioproliferative anti-Thy 1.1-GN, immune cells
carry and rapidly release sPLA2-IB protein inside the
glomerulus. The sPLA2-IB protein subsequently activates
the resident cells to further enhance their production by an
autocrine loop.
Expression of the M-type sPLA2 receptor under inflammatory
conditions in vivo and in vitro
Immunofluorescence analysis shows that the sPLA2 receptor
is not detectable in control kidneys (Figure 6a), although the
receptor was previously detected by sPLA2-binding assay with
labeled OS1 ligand.35 However, 6 h after anti-Thy 1.1-GN
induction, there was a clear staining of receptor protein in
distinct cells inside the glomeruli (Figure 6b).
We next investigated the expression levels of the M-type
sPLA2 receptor in vitro on isolated glomerular mesangial and
endothelial cells and on cells isolated from the PBL fraction.
Unstimulated primary rat mesangial cells grown in vitro do
not express the sPLA2 receptor mRNA (Figure 7a, right
panel) and protein (Figure 7b, right panel); however, there is
a strong upregulation by IL-1b. On the other hand, a weak
basal expression of the M-type sPLA2 receptor mRNA and
protein was found in GECs (Figure 7a, left panel), which was
also increased by treatment with IL-1b (Figure 7b, left panel).
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Figure 4 | Expression of sPLA2-IB in rat glomerular mesangial and
endothelial cell cultures. Cells were cultured as described in
Materials and Methods and were treated for 24 h with TNFa (1 nM)
and/or IL-1b (1 nM) or sPLA2-IB (1 mM) from bovine pancreas or
recombinant H48Q- sPLA2-IB (1 mM). (a) Semiquantitative RT-PCR was
performed to detect the expression of mRNA of sPLA2-IB. GAPDH
expression was used as an internal control. (b) Protein was
precipitated from 2 ml of cell culture supernatants and Western blot
analysis was performed as described in Materials and Methods to
detect sPLA2-IB in untreated and cytokine-treated cells. As a positive
control, 3 mg of porcine sPLA2-IB were loaded on the gel.
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Figure 5 | Regulation of the expression of sPLA2-IB in PBLs by
IL-1b. PBLs were isolated from rat whole blood as described in
Materials and Methods, separated into monocytes, lymphocytes and
granulocytes, and treated for the indicated periods with IL-1b (1 nM).
The experiments were performed three times with comparable
results. (a) sPLA2-IB mRNA expression was determined by semi-
quantitative RT-PCR and GAPDH was used as an internal control.
(b) Western blot analysis of sPLA2-IB in cell culture supernatants of
monocytes and in lysates of lymphocytes and granulocytes before
and after the indicated incubation periods with IL-1b (1 nM) was
performed as described in Materials and Methods. (c) As a positive
control, 3 mg of porcine sPLA2-IB were loaded on the gel. As a loading
control for the lysates, we investigated the expression of b-actin.
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Figure 6 | Expression of the M-type sPLA2 receptor in nephritic
kidneys. Immunofluorescence analysis of the M-type sPLA2 receptor
protein expression was performed in paraffin sections of kidneys
obtained from (a) control rats and (b) from rats at 6 h after disease
induction original (magnification  630).
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Interestingly, we found that lymphocytes also express the
M-type sPLA2 receptor mRNA, and this expression can be
upregulated by IL-1b stimulation (Figure 8a, left panel).
Granulocytes show the same pattern of expression (Figure 8a,
right panel). Conversely, monocytes express only very low
levels of the receptor mRNA, which is not increased by IL-1b
(Figure 8a, left panel). Western blot analysis for the receptor
was not possible because of the low amount of protein
obtained from the cell preparations.
Therefore, immunofluorescence studies with antibodies
against the M-type sPLA2 receptor (Figure 8b) and HIS-48
(Figure 8b, c) or ED-1 on kidney sections show that some
cells expressing the M-type sPLA2 receptor protein are also
positive for HIS-48 (Figure 8b, d), whereas ED-1-positive
cells do not carry the receptor (data not shown).
DISCUSSION
The expression of sPLA2-IB was previously found to be
increased in the kidney during acute pancreatitis.3 sPLA2-IB
was also proposed to trigger the formation of proinflamma-
tory lipid mediators via activation of the mitogen-activated
protein kinase cascade and cPLA2,
8,9 to stimulate the
proliferation of mesangial cells7 and to activate rat renal
mesangial cells via its specific M-type receptor, thereby
leading to the expression of proinflammatory enzymes like
the inducible nitric oxide synthase36 and sPLA2-IIA.
9 Here we
show for the first time that the expression of both sPLA2-IB
and its receptor is dramatically increased in kidneys during
mesangioproliferative anti-Thy 1.1-GN. These data further
support the possibility that sPLA2-IB behaves as an in vivo
ligand for the M-type sPLA2 receptor.
sPLA2-IB is most exclusively detected in cells within the
glomeruli, as was shown by immunohistochemical analysis,
and these turned out to be mostly invading immune cells.
The weak staining in the vicinity of the glomeruli and in the
interstitium might be owing to sPLA2-IB in BM-8 cells and
CD3þ -positive lymphocytes or dendritic cells, respectively,
as it has been observed that these types of cells can be found
in this area in GN-like kidney injury in mice.37,38 We did not
elucidate if this staining is owing to sPLA2-IB as there was a
clearly predominate enzyme expression in the glomerulus
covering this marginal effect. In isolated immune cells in
vitro, monocytes and granulocytes represent the main source
of sPLA2-IB. In good agreement with these results, these cells
are among the earliest immune cells invading the glomeruli
after induction of anti-Thy 1.1-GN.16,17,39 In particular,
monocytes constitutively express sPLA2-IB mRNA and
protein, and this may explain the drastic increase of this
enzyme in the kidney extracts after disease induction.
Interestingly, after IL-1b stimulation, sPLA2-IB secretion
from monocytes is enhanced, whereas sPLA2-IB mRNA in
these cells is even downregulated. The situation is comparable
to that in HIS-48-positive neutrophils, where it was described
that sPLA2-IB is stored as inactive zymogen, and after
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Figure 7 | Detection of M-type sPLA2 receptor expression in
glomerular endothelial and mesangial cell cultures. (a) mRNA
expression of the M-type sPLA2 receptor in RNA extracts of GEC
and GMCs was performed by semiquantitative RT-PCR as described
in Materials and Methods. GAPDH was used for standardization.
(b) M-type sPLA2 receptor protein was detected in unstimulated
and cytokine-stimulated GECs and GMCs by Western blotting
using a specific antibody (1:500) as described in Materials and
Methods. (c) As a positive control, 2 ng of recombinant receptor
protein were loaded on the gel. As a control for equal protein
amounts, we investigated the expression of b-actin.
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Figure 8 | Detection of M-type sPLA2 receptor expression in PBLs
in vitro and in immune cells in vivo. (a) PBLs were isolated from rat
whole blood and were fractionated into monocytes, lymphocytes,
and granulocytes as described in Materials and Methods. Cells were
stimulated with IL-1b (1 nM) for the indicated periods of time.
Semiquantitative RT-PCR was performed to detect receptor mRNA
and GAPDH or 18S RNA as an internal control. For confocal laser
scanning microscopy, paraffin sections from kidneys obtained at 6 h
after disease induction (pretreated with an anti-mouse IgG antibody
(c¼ 0.5mg/ml)) were co-incubated with antibodies specific for the
M-type sPLA2 receptor (1:10) and HIS-48 (1:2), and detection was
performed with 1:400 dilution of Alexa 488-conjugated goat anti-
rabbit IgG (green) for the (b) receptor and (c) Alexa 594-conjugated
goat anti-mouse IgG (red) for HIS-48-positive cells, respectively, using
a confocal laser scanning microscope original (magnification  400).
(d) Merge – colocalization of both antibodies.
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cytokine stimulation the precursor and native enzyme are
released from these cells.40 In vivo studies in rat neutrophils
about sPLA2-IB expression have not yet been performed.
Thus, the present study is the first report showing the
expression of sPLA2-IB in these cells in anti-Thy 1.1-GN. Six
hours after induction of the disease, HIS-48-positive
neutrophils invade into the glomeruli and start to express
sPLA2-IB. We could show this as well in in vitro studies with
granulocytes isolated from the PBL fraction of rats. Already
3 h after stimulating the cells with IL-1b, they start to express
sPLA2-IB mRNA, reaching a maximum in production after
6 h. According to this high mRNA expression, the granulo-
cytes contain very high amounts of the enzyme.
We also analyzed the expression of sPLA2-IB by resident
renal cells under the conditions of a mesangioproliferative
type of GN.
Glomerular endothelial cells in vitro express low levels of
sPLA2-IB mRNA and constantly release small amounts of
sPLA2-IB protein; however, there is only a weak upregulation
after cytokine treatment. This basal sPLA2-IB protein
expression may explain the weak immunostaining of the
glomeruli in the control kidneys for some housekeeping
functions. By treating the endothelial cells with exogenously
added sPLA2-IB, we mimicked the early stages of anti-Thy
1.1-GN when invading immune cells bring in high amounts
of sPLA2-IB. Under these conditions, we could show a very
strong induction of the endogenous sPLA2-IB mRNA
production. It is possible that the endogenously produced
enzyme is acting on its own synthesis via a positive feedback
loop as it has already been described for sPLA2-IIA in renal
rat mesangial cells.9 Interestingly, the catalytically inactive
mutant H48Q sPLA2-IB
41 can also induce the endogenous
enzyme. This supports our hypothesis that exogenous sPLA2-
IB exerts its effects on its own synthesis rather receptor-
mediated than via its enzymatic action.
Mesangial cells do not express sPLA2-IB mRNA or
protein, and thus any staining of sPLA2-IB in these cells is
most likely owing to endocytosis of extracellular sPLA2-IB
protein via the M-type sPLA2 receptor. On the other hand, in
this cell type, sPLA2-IB together with TNFa-stimulation is
able to trigger the expression of sPLA2-IIA.
9 It has been
shown that sPLA2-IIA enhances the proliferation response of
these cells. Furthermore, sPLA2-IIA has been demonstrated in
high amounts at the lesions of inflammation in damaged
glomeruli and a high content of the enzyme has also been
found in monocytes/macrophages.42 After induction of
Thy1.1-GN, sPLA2-IIA mRNA is upregulated in a time-
dependent manner (data not shown). Taken these facts into
account, there is a strong evidence that sPLA2-IIA acts as an
autocrine and/or paracrine mediator in the progression of
GN.
sPLA2-IB is the only sPLA2 subtype known so far to bind
with high affinity to the rat M-type sPLA2 receptor
(KD¼ 0.5 nM; Beck et al.9, Valentin and Lambeau11 and
Lambeau et al.43). Earlier studies in rat mesangial cell cultures
have shown that sPLA2-IB, independently of its catalytic
activity, stimulates the expression of the proinflammatory
sPLA2-IIA and prostaglandin formation.
8,12 Recently, we have
shown that this process involves the activation of the
transcription factor, peroxisome proliferator-activated recep-
tor a,9 and proposed an important role for the M-type sPLA2
receptor in this process. In the present study, we show for the
first time that the expression of the M-type sPLA2 receptor is
dramatically upregulated at mRNA and protein levels during
GN. In particular, resident glomerular cells of the nephritic
kidneys express high amounts of the receptor. In vitro, IL-1b-
stimulated rat primary mesangial cells show a massive
upregulation of the receptor at mRNA and protein level,
and thus all the cellular effects observed by exogenously
added sPLA2-IB in mesangial cells may be augmented in the
presence of proinflammatory cytokines owing to an increase
in the M-type receptor number.
Interestingly, GECs were found to constitutively express
low receptor mRNA and protein levels, which were
upregulated after IL-1b treatment. We have observed earlier
that human lung microvascular endothelial cells respond to
sPLA2-IB treatment with a nuclear factor kappa kB- and
extracellular signal-regulated protein kinase-1/-2-mediated
upregulation of inflammatory chemokines.44 It is tempting
to speculate that GECs, which show an enhanced M-type
sPLA2 receptor expression during inflammatory conditions,
respond in a similar manner to the massive increase in
sPLA2-IB protein by upregulating proinflammatory genes.
Regarding the invading immune cells, we detected a strong
upregulation of the M-type sPLA2 receptor mRNA in IL-1b-
stimulated lymphocytes as well as in granulocytes. Concern-
ing the lymphocytes, Yokota et al.45 made a similar
observation at the protein level in lymphocytes of mice
spleen during lipopolysaccharide-induced endotoxic shock.
During anti-Thy 1.1-GN, lymphocytes appear at 24 h after
disease induction, reaching a maximum after 7 days.46 Thus,
an enhanced sPLA2-IB expression together with an increased
M-type sPLA2 receptor level in lymphocytes may contribute
to inflammatory signaling mechanisms during the delayed
progression of GN.
The presence of M-type receptor on neutrophils has been
described earlier.47 According to our data on the strong
induction of the M-type sPLA2 receptor mRNA together with
the production of high amounts of sPLA2-IB in granulocytes,
this cell type might be responsible for the very early onset of
anti-Thy 1.1-GN cell damage.
Because of its internalization properties,48 the M-type
sPLA2 receptor may play a role in the clearance of sPLA2-IB
from the extracellular fluid. On the other hand, we have
recently shown that the activation of peroxisome proliferator-
activated receptora by sPLA2-IB in rat mesangial cells
enhances the cytokine-stimulated induction of the pro-
inflammatory sPLA2-IIA by a mechanism independent of its
catalytic activity and possibly via the M-type sPLA2 receptor
and activation of cPLA2.
9 sPLA2-IB may therefore indirectly
mediate the formation of endogenous lipids that serve as
ligands for peroxisome proliferator-activated receptor a
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activation in rat mesangial cells via activation of cPLA2 and
eicosanoid-generating enzymes (Beck et al.9 and citations
herein), and thereby may contribute to the onset of
inflammatory processes.49
The development of specific sPLA2 receptor antagonists
might be a new therapeutic approach for the treatment of
mesangioproliferative GN.
MATERIALS AND METHODS
Materials
IL-1b was obtained from Cell Concept (Umkirch, Germany). TNFa
was a generous gift from Knoll AG (Ludwigshafen, Germany).
Horseradish peroxidase-conjugated goat anti-rabbit IgG was from
Amersham-Pharmacia (Freiburg, Germany). Immobilon-polyvinyl-
idine difluoride membranes were obtained from Millipore
(Eschborn, Germany). Skim milk powder was obtained from Sigma
(Taufkirchen, Germany). All other chemicals used were from either
Sigma, Biomol (Hamburg, Germany) or Calbiochem (Bad Soden,
Germany). All cell culture media and nutrients were from Invitrogen
(Eggenstein, Germany). Goat serum was obtained from SantaCruz
Biotechnology (Heidelberg, Germany), Proteinase K from Qiagen
(Hilden, Germany), and DAKO Fluorescent Mounting Medium
from DAKO-corporation (Hamburg, Germany). Anti-rat neutrophil
antibody HIS-48 and anti-monocyte antibody ED-1 were a kind gift
from Dr P Heeringa (University of Maastricht, The Netherlands).
The polyclonal antibody against rat sPLA2-IB was generated in
rabbit as described earlier3,34 and was diluted in 50% glycerol.
Rabbit anti-serum directed against the mouse M-type receptor was
prepared by immunizing the rabbit with 100 mg of purified soluble
mouse M-type receptor produced as described previously for the
rabbit soluble M-type receptor.50 Anti-mouse IgG antibody
produced in goat was obtained from R&D Systems (Wiesbaden,
Germany) and anti-b-actin antibody produced in mouse from
Sigma, Biomol (Hamburg, Germany). Recombinant sPLA2-IB and
the mutant form sPLA2-IB-H48Q were produced as described (6),
and porcine and bovine sPLA2-IB were purchased from Sigma
Biomol (Hamburg, Germany). All enzymes were endotoxin-free as
tested by the Limulus amebocyte lysate assay from BioWhittaker
(Wakersville, MD, USA).
Experimental model and experimental design
of anti-Thy 1.1-GN in rats
All animal studies were approved by the Institutional Review Board.
Anti-Thy-1.1 mesangial proliferative GN20 was induced in male
Wistar rats (Charles River, Sulzfeld, Germany), weighing 140–160 g
at the start of the experiment, by injection of 1 mg/kg monoclonal
anti-Thy-1.1 antibody (clone OX-7; European Collection of Animal
Cell Cultures, Salisbury, UK). The animals were killed at different
time points (0, 2, 6, 24 h, 7 days, 14 days) with n¼ 3 for each time
point. The kidneys were used for the isolation of RNA and protein
or were formalin-fixed for preparation of paraffin sections.
Cell culture
Primary rat mesangial cells were isolated, cultured, and character-
ized as described for mouse mesangial cells, except that b-mercapto-
ethanol was omitted.51 Cells were grown in Rosewell Park Memorial
Institute media 1640 supplemented with glutamax I and 10% fetal
calf serum (FCS), penicillin (100 U/ml), streptomycin (100 mg/ml),
non-essential amino acids, 4-(2-hydroxyethyl)-1-piperazineethane-
sulphonic acid buffer (25 mM), and bovine insulin (0.66 U/ml), and
used for experiments between passages 12 and 16. Twenty-four
hours before stimulation and during the experiments, cells were
incubated in serum-free Rosewell Park Memorial Institute media
(see above) containing 0.1 mg/ml fatty acid-free bovine serum
albumin (BSA).
Rat GECs were cultured as described52 in Dulbecco’s modified
Eagle’s medium with 10% FCS, penicillin (100 U/ml), streptomycin
(100 mg/ml), and bovine insulin (0.66 U/ml). One hour before
stimulation and during the experiment, cells were incubated in the
same medium but with reduced serum content (2.5% FCS).
Rat peripheral blood leukocytes (PBL fraction) were obtained
from fresh heparinized rat blood. One part of Ficoll was covered
with two parts of diluted blood (1:2 with phosphate-buffered saline
(PBS)) and centrifuged for 20 min at 1 600 r.p.m. Monocytes and
lymphocytes from the PBL fraction were isolated by three rounds of
centrifugation (10 min at 2200 r.p.m., then 1600 r.p.m., then
1000 r.p.m.) and washing with PBS. Monocytes and lymphocytes
were separated by negative immunoselection with a CD-4 isolation
kit (Miltony Biotec, Bergisch-Gladbach, Germany) and adherence to
plastic dishes, respectively. Lymphocytes represent most of the cells
from the non-adherent cell fraction. Each cell fraction was cultured
in 10% FCS for 2 days, starved in 1% FCS, and then treated for 2, 6,
and 24 h with IL-1b.
For the isolation of granulocytes, the supernatant from the first
centrifugation step was removed, and cells from the bottom layer of
the Ficoll gradient were taken. The cells were diluted with 4 ml of
PBS and 1 ml of 5% dextran solution per 2.5 ml heparinized blood.
This suspension was transferred into a glass tube and sedimented for
45 min. The supernatant was transferred carefully into a fresh tube
and centrifuged for 10 min at 1000 r.p.m. The pelleted cells were
resuspended in 1 ml of ice-cold distilled water, mixed for 20 s,
washed with PBS, and centrifuged for 10 min at 1000 r.p.m. The
resulting cell pellet was resuspended in medium for further
experiments.
Immunohistochemical analysis
Kidney sections embedded in paraffin were de-waxed (2 5 min in
xylene), re-hydrated in 100 and 96% ethanol (each 2 10 min),
double-distilled water (1 5 min), and then equilibrated in PBS. For
demasking the protein surface, sections were incubated with
proteinase K (1.5 mg/ml) for 10 min, washed with PBS and treated
with 15% goat serum/PBS for blocking. The slides were incubated
for 12 h at 41C with or without anti-rat sPLA2-IB antibody diluted
1:500 in 15% goat serum/PBS. The sections were then rinsed three
times with PBS and incubated at room temperature for 35 min with
an alkaline phosphatase-conjugated goat anti-rabbit IgG secondary
antibody diluted 1:100 in 2% BSA. The sections were rinsed as
described above and incubated in DAKO alkaline phosphatase fast
red substrate-chromogen system (DAKO-corporation, Hamburg,
Germany), containing fast red tablets, buffered substrate, and
levamisole. The staining time was controlled by microscopic
observation. Finally, the alkaline phosphatase-labeled sections were
counterstained with hematoxylin.
Immunofluorescence Studies
Paraffin sections were prepared as described above. In the case of the
kidney sections from animals treated with the anti-Thy-1.1
antibody, it was necessary to block the IgG binding sites of mouse
origin with an anti-mouse IgG antibody (c¼ 0.5 mg/ml) for 12 h at
41C before the use of the monoclonal antibodies against HIS-48 and
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ED-1. This pretreatment prevents false-positive signals, which are
owing to the binding of the Alexa 594-conjugated goat anti-mouse
IgG to the anti-Thy-1.1 antibody. After washing for 30 min, we
proceeded with adding the appropriate antibody as described below.
The slides were incubated for 12 h at 41C either with antibodies
against sPLA2-IB (1:400), HIS-48 (1:2), ED-1 (1:2), or M-type
sPLA2 receptor (1:10), respectively. All antibody dilutions were
prepared in 15% goat serum/PBS. As a negative control, sections
were incubated with 15% goat serum/PBS omitting the primary
antibody but not the blocking reaction with the anti-mouse IgG
antibody. After washing with PBS, the sections were incubated for
30 min at room temperature with 1:400 dilutions (in 15% goat
serum/PBS) of the appropriate secondary antibodies carrying a
fluorescent label. Alexa 488-conjugated goat anti-rabbit IgG was
used for the detection of sPLA2-IB and M-type sPLA2-receptor. For
colocalization studies, the sections were incubated simultaneously
with an Alexa 594-conjugated goat anti-mouse IgG diluted 1:400 for
the detection of HIS-48- or ED-1-positive cells. Finally, the sections
were washed with PBS and embedded in mounting medium.
Pictures were taken by using a confocal laser scanning microscope
(Zeiss Axiovert 100M/LSM 510).
Semiquantitative RT-PCR
Expression of the desired mRNAs was analyzed by semiquantitative
RT-PCR using 5 mg of total RNA. First-strand cDNA was prepared
with SuperScript II RNase H-reverse transcriptase (Invitrogen,
Eggenstein, Germany) and oligo(dT)15 primer (Promega, Man-
nheim, Germany) for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) standardization or random hexamer primers (Applied
Biosystems, Darmstadt, Germany) for 18S RNA standardization.
PCR was performed on a Perkin-Elmer Thermal Cycler using a
prepared Mastermix containing deoxynucleoside triphosphates,
specific primers, and Red Taq polymerase (Sigma, Taufkirchen,
Germany). For the PCR reactions, the following primer sequences
were used: sPLA2-IB, sense (5
0-CCTCGCCAAGATGAAACTCC-30),
antisense (50-CGGTGCAGAAATAAGACAGC-30), amplified product
513 bp; M-type sPLA2 receptor, sense (5
0-TGCACCCTGGCTCTTC
TATCA-30), antisense (50-CGCATCGCTTTCTCTGGCTAT-30), am-
plified product 304 bp; GAPDH, sense (50-ACCACAGTCCATGC
CATCAC-30), antisense (50-TCCACCACCCTGTTGCTGTA-30), and
amplified product 452 bp. 18S RNA: sense (50-GCGGTAATTCCAGC
TCCAATAG-30), antisense (50-CCCTCTTAATCATGGCCTCAGT-30),
amplified product 289 bp.
The following PCR conditions were used: sPLA2-IB – 941C for
4 min (one cycle) followed by 941C for 1 min, 561C for 60 s, 721C for
3 min (30 cycles), and a final extension at 721C for 10 min. M-type
sPLA2 receptor – 941C for 1 min (one cycle), followed by 941C for
1 min, 601C for 1 min, 721C for 1 min (28 cycles), and a final
extension at 721C for 10 min. GAPDH – 941C for 1 min (one cycle)
followed by 941C for 1 min, 601C for 1 min, 721C for 2 min (23
cycles), and a final extension at 721C for 10 min. 18S RNA –951C for
4 min (one cycle) followed by 951C for 1 min, 601C for 1 min, 721C
for 2 min (24 cycles), and a final extension at 721C for 10 min. The
amplified PCR products were separated on 1.0% agarose gels
containing 0.5mg/ml ethidium bromide.
Quantitative real-time PCR
Total RNA was isolated using Trizol-Reagent (Invitrogen, Eggen-
stein, Germany) according to the manufacturer’s instructions.
DNase digestion was performed before reverse transcription to
exclude amplification of genomic DNA. Five hundred nanograms of
total RNA was reverse transcribed into cDNA according to the
manufacturer’s instructions (Roche, Mannheim, Germany), using
the first-strand cDNA synthesis kit. cDNA was diluted in 20 ml
diethyl pyrocarbonate-treated water and stored at 301C until
quantitative real-time PCR was performed with a Light Cycler
(Roche, Mannheim, Germany). The oligonucleotides of sPLA2-IB
used for real-time PCR are listed above. Specific DNA standards
were generated by PCR amplification of cDNA, purification of the
amplified products, and quantification by spectrophotometry. Real-
time PCR of cDNA specimen and DNA standards were performed in
a total volume of 25 ml, containing 2 ml FastStart DNA Master SYBR
Green I, 10 pmoles of gene-specific forward and reverse primers,
2 mM MgCl2, and 11.5ml of water. The amplification profile for each
sample was as follows: 2 min at 501C, 5 min at 951C followed by
45–55 cycles of amplification; each amplification cycle consisting of
denaturation at 951C for 15 s and annealing/extension at 60/721C
for 1 min. Standard curves were generated for all genes. PCR
efficiency was assessed from the slopes of the standard curves and
was found to be between 90 and 100%. The linearity of the assay
could be demonstrated by serial dilution of all standards and cDNA.
All samples were normalized for an equal expression of GAPDH.
Each experiment was repeated three times with similar results.
Western blot analysis
sPLA2-IB protein was detected by Western blot after precipitating a
2 ml sample of cell culture supernatant from GECs, mesangial cells,
lymphocytes, or monocytes with 800ml of 20% trichloroacetic acid.
Protein lysates from rat kidneys were prepared by homogenizing the
tissue by sonication in a buffer consisting of 50 mM Tris/HCl (pH
7.5), 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, and 10mg/
ml leupeptin. The same buffer and conditions were used for
preparing protein lysates from harvested cells. Three micrograms of
sPLA2-IB from porcine pancreas (Sigma, Taufkirchen, Germany)
were loaded as a positive control. The protein samples were boiled
(5 min, 951C) before loading. Sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis using a 15% polyacrylamide gel was
performed under reducing conditions with 25 mM dithiothreitol in
2 Laemmli buffer. The proteins were transferred to Immobilon-
polyvinylidine difluoride membranes for 45 min at 0.7 mA/cm2.
Nonspecific binding was blocked with 2% BSA in PBS/0.05%
Tween-20 for 1 h at room temperature followed by incubation with a
polyclonal antibody raised against rat sPLA2-IB
3 at a 1:1000 dilution
in 2% BSA in PBS/0.05% Tween-20. The blot was then incubated
with horseradish peroxidase-conjugated goat anti-rabbit IgG
(Amersham Pharmacia Biotech, Freiburg, Germany) at a 1:15 000
dilution in 2% BSA in PBS/0.05% Tween-20 for 1 h at room
temperature. The washing steps were performed in 0.05% Tween-20
in PBS. After washing, peroxidase activity was detected by using the
chemiluminescence system enhanced chemiluminescence (Amer-
sham Pharmacia Biotech, Freiburg, Germany) according to the
manufacturer’s instructions.
To analyze the expression of the M-type sPLA2-receptor, rat
glomerular endothelial and mesangial cells were lysed by sonication
(10 s, 20% on a Braun Sonifier) in a buffer consisting of 20 mM Tris/
HCl, 1 mM ethylenediaminetetraacetic acid, 1 mM ethyleneglycol
tetraacetate, 0.25 mg/ml leupeptin, and 0.1 mM phenylmethylsulfonyl
fluoride (pH 7.5). The cell lysates were centrifuged for 5 min at
4000 r.p.m. to remove cellular debris. Homogenates of rat kidney
were prepared in the same lysis buffer. Two nanograms of
recombinant soluble mouse M-type sPLA2 receptor were used as a
positive control. For Western blot analysis, protein samples were
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separated on a 7% polyacrylamide gel under non-reducing
conditions without boiling before loading. Transfer of the proteins
to Immobilon-polyvinylidine difluoride membrane was performed
for 60 min at 0.7 mA/cm2. Then, the blot was washed twice with
distilled water before overnight blocking at 41C in Tris-buffered
saline Tween-20 (TTBS) (20 mM Tris-HCl, 137 mM NaCl, 0.1%
Tween-20, pH 7.6) with 5% milk powder. The following washing
and incubation steps were performed at room temperature. The blot
was rinsed two times with TTBS and then incubated for 2 h with the
anti-mouse M-type sPLA2-receptor antibody at a dilution of 1:500
in TTBS. After washing with TTBS (3 10 min), secondary
antibody (horseradish peroxidase-conjugated goat anti-rabbit IgG)
at a 1:15 000 dilution in TTBS was added for 1 h. Finally, the blot
was rinsed with TTBS (3 10 min) and prepared for enhanced
chemiluminescence detection, as described above.
As an internal loading control, the membranes of the Western
blots of the lysates have been incubated with anti-b-actin antibody
produced in mouse (diluted 1:10 000 in blocking buffer) after
blocking with 2% BSA in PBS/0.05% Tween-20 for 30 min at room
temperature. After washing, the blot has been treated with
horseradish peroxidase-conjugated goat anti-mouse IgG (Amersham
Pharmacia Biotech, Freiburg, Germany) at a 1:15 000 dilution in
2% BSA in PBS/0.05% Tween-20 for 30 min at room temperature.
The washing steps were performed in 0.05% Tween-20 in PBS.
After washing, peroxidase activity was detected by using the
chemiluminescence system enhanced chemiluminescence.
Statistical analysis
Data are represented as means7s.d. (n¼ 3) showing one repre-
sentative experiment of three with similar results. Statistical analysis
was performed by Student’s t-test. A probability o0.05 was
considered as significant. The animal studies concerning the anti-
Thy-1.1 mesangial proliferative GN were performed four times in
independent experimental series as described above and the results
from one representative series are shown.
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